The value of patient-based cell models and brain organoids in unpicking the complexities of neurodegenerative diseases is again highlighted in new research showing how mutations that cause a rare subtype of Parkinson's disease operate at a cellular level.
Using stem cells derived from members of families carrying mutations in the PARK7 gene that are linked to an early onset form of Parkinson's disease, the researchers at the University of Luxembourg directly observed that these defects disrupt exon splicing.
That interferes with the activity of a small RNA called U1, reducing production of the DJ-1 protein (also called Parkinsonism associated deglycase), which among other functions, is involved in mitochondrial regulation. The researchers found that mitochondria in the patient-derived cell models malfunctioned as a result.
Based on this insight, Ibrahim Boussaad and colleagues designed a combination therapy that repaired these aberrations, halting the death of dopaminergic neurons in brain organoids.
The researchers say the study, published in the latest issue of Science Translational Medicine, provides a foundation to develop therapies that could help correct the genetic cause of some forms of Parkinson's disease.
"When PARK7 was first discovered it was described as causing the substitution of an amino acid. It's only when we got patient material we could see it's not substitution. We saw it was a problem with splicing," Boussaad told BioWorld Science.
There are more than 25 PARK7 gene mutations that are implicated in Parkinson's disease. However, it previously was unclear how loss of functional DJ-1 protein causes the neurodegenerative disease, with some studies suggesting PARK7 mutations disrupt the protein's chaperone function, leading to a toxic buildup of misfolded proteins, while others suggest PARK7 mutations impair DJ-1's ability to protect cells from oxidative stress.
Boussaad said the researchers were aiming to pinpoint specific defects in the mutant DJ-1 protein generated by the patient cell models. Instead, they found there was little or no trace of the protein at all.
The possibility that the protein was unstable and had degenerated was excluded by blocking degradation pathways to show there were no metabolites of the protein.
"So we took a step back and started to look upstream. We could detect [PARK7] RNA, but it was shorter," said Boussaad. "On sequencing the products, we saw an entire section of RNA was missing."
Luckily, one of the donors was heterozygous for PARK7, and in this case it was possible to detect both normal length and shorter RNA, helping to confirm that mis-splicing was blocking DJ-1 production.
The researchers showed it was possible to correct the defective exon skipping using genetically engineered U1-snRNA (small nuclear RNA). That corrected DJ-1 expression in neuronal precursor cells and differentiated neurons.
They also demonstrated that combination treatment with the small molecules RECTAS (rectifier of aberrant splicing) and phenylbutyric acid repaired the splicing defects, restoring DJ-1 production, correcting mitochondrial function and preventing loss of dopaminergic cells in mutant PARK7 brain organoids.
Looking at sequence databases, the researchers found that similar splicing mutations appeared more frequently in the genomic data from 2,710 patients with the common sporadic form of Parkinson's disease, than in data from 5,713 controls, pointing to a wider significance of the current study.
With the literature suggesting that as many as a third of all disease-causing mutations exert their effects through faulty exon splicing, the findings could also have relevance to other conditions.
The direct observation of the cellular-level impact of one of these mutations and the possibility of therapeutic intervention, should lead to greater focus in this area, Boussaad said. "There are a few other such mutations known and described, but they have not got the attention they should have in the field of neurodegenerative diseases."
As a next step, the researchers plan to further develop the combination treatment. "We are going into animal models to see how potent it is in entire organisms. We also want to look at availability in the brain and if compounds have the ability to cross the blood-brain barrier," said Boussaad. "And of course, the other direction will be to further explore the abundance of exon splicing mutations in Parkinson's disease."
It is becoming increasingly clear that although patients with Parkinson's present with the same motor symptoms, there are subtypes of the disease which have different etiologies. "To advance treatment, we have to stratify. We have to investigate for each patient, why they have this disease," Boussaad said.
That could form the basis of customized treatments. "If we can identify patients with exon splicing mutations it will have positive benefits. If they can be corrected, it will restore the protein and be neuroprotective, rather than treating the symptoms," said Boussaad. "It could have a significant impact." (Boussaad, I. et al. Sci Transl Med 2020, 12: eaau3960).
Read the original post:
- The Top 10 Biotech Companies Brewing at... - Labiotech.eu - September 18th, 2020
- CRISPR Market to Witness Exponential Growth by 2020-2027 | Leading Players Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR... - September 18th, 2020
- Case 29-2020: A 66-Year-Old Man with Fever and Shortness of Breath after Liver Transplantation - nejm.org - September 18th, 2020
- Frequency Therapeutics Presents Results Demonstrating Sustained Improvement in Hearing Loss Patients Treated with FX-322 - Business Wire - September 18th, 2020
- Treating dogs diagnosed with GBM, getting Swedish patients back to work, orphan designation for improved radiotherapy drug plus gene therapy - Brain... - September 13th, 2020
- Histogen Announces Completion of Dosing Milestone in its 1b/2a Trial for Androgenic Alopecia in Men - StreetInsider.com - September 13th, 2020
- BeyondSpring (BYSI) Receives Breakthrough Therapy Designations from Both US FDA and China NMPA for Plinabulin in Chemotherapy-Induced Neutropenia... - September 8th, 2020
- Hematopoietic Stem Cells (HSCs) Market 2020: Potential Growth, Challenges, and Know the Impact of COVID-19 on Industry | Key Players: Kite Pharma... - September 8th, 2020
- Stem Cell Therapy Market Scope and Opportunities Analysis 2017 2025 - StartupNG - August 31st, 2020
- Im Optimistic That We Will Have a COVID-19 Vaccine Soon - The Atlantic - August 31st, 2020
- Health insurance with maternity cover: All you need to know about features and inclusions - CNBCTV18 - August 31st, 2020
- Emerging Treatment Options of Regenerative Medicine in Severe Corona Virus/COVID 19 Infections - DocWire News - August 31st, 2020
- MaaT Pharma Announces Positive Data for Its Lead Microbiome Biotherapeutic MaaT013 in Intestinal Acute Graft-versus-Host-Disease at the Virtual 46th... - August 31st, 2020
- Exosome Therapeutic Market 2020-2026 is Growing So Rapidly || Leading Players THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United... - August 20th, 2020
- Inside the race to ditch formula and grow breast milk in the lab - Wired.co.uk - August 20th, 2020
- Animal Stem Cell Therapy Market: Rising Demand and Growth Opportunity - Owned - August 20th, 2020
- Health Spotlight: Have You Heard Of Dr. Jeffrey Tucker? - LATF USA - August 20th, 2020
- Viruses have big impacts on ecology and evolution as well as human health - The Economist - August 20th, 2020
- Merck's KEYTRUDA (pembrolizumab) in Combination With Chemotherapy Significantly Improved Overall Survival and Progression-Free Survival Compared With... - August 20th, 2020
- Umbilical cord blood banking: Is it worth it? - mtltimes.ca - August 19th, 2020
- G1 Therapeutics Announces Acceptance and Priority Review of NDA for Trilaciclib for Patients with Small Cell Lung Cancer - GlobeNewswire - August 19th, 2020
- A question of scale the growing pains of cell-based meat - just-food.com - August 19th, 2020
- What do we need to know about our bone health during this pandemic - Times of India - August 19th, 2020
- Researcher John Craig Venter Is Awarded the 2020 Edogawa-NICHE Prize for His Accomplishment in Human Genome Research - Business Wire India - August 19th, 2020
- Cellect Biotechnology Ltd ADR (NASDAQ:APOP) Receives an Approval of a Pivotal Patent for Stem Cells Activation from the European Patent Office - BP... - August 13th, 2020
- A rapid, sensitive, and reproducible in vivo PBMC humanized murine model for determining therapeuticrelated cytokine release syndrome - Wiley - August 13th, 2020
- Autologous Stem Cell Based Therapies Industry Market 2020 Explain What is the current size of the market? And key players analysis: Athersys,... - August 13th, 2020
- Dr. Park on the Benefits of Off-the-Shelf CAR T-Cell Therapy in ALL - OncLive - August 11th, 2020
- CELLECTAR BIOSCIENCES : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - marketscreener.com - August 11th, 2020
- Trumps Unprecedented Attacks on Our Public-Health System - The New Yorker - August 11th, 2020
- New Report: Regenerative Medicine & Advanced Therapies Sector Thriving Despite COVID-19 - PharmiWeb.com - August 11th, 2020
- The NIU BODY Rebrand: millennials have grown up and so has their skin care - CosmeticsDesign.com USA - August 11th, 2020
- Embryos could be susceptible to COVID-19 from second week of pregnancy - Gulf News - August 9th, 2020
- Coronavirus Live Updates: Latest News and Analysis - The New York Times - August 9th, 2020
- How to live longer: The health drink that reduces risk of Alzheimers and boosts longevity - Express - August 9th, 2020
- The global cell and gene therapy market by revenue is expected to grow at a CAGR of over 30.90% during the period 20192025 - GlobeNewswire - August 5th, 2020
- Research Report on Cell Theraputics Market by Current Industry Status, Growth Opportunities, Top Key Players, and Forecast to 2025 - AlgosOnline - August 5th, 2020
- Pediatrics in Brevard: Nothing beats the benefits of breastmilk for newborns - Florida Today - August 5th, 2020
- How can nanomedicine be applied to cannabis? - Leafly - August 5th, 2020
- Cell Expansion Market Analytical Overview, Growth Factors, Demand, Trends and Forecast to 2027 - CueReport - August 5th, 2020
- FDA hands MorphoSys and Incyte a quick OK on their potential blockbuster CAR-T alternative - Endpoints News - August 5th, 2020
- Fighting for a life unlimited with the Cystic Fibrosis Trust - Health Europa - August 5th, 2020
- World Breastfeeding Week 2020: The Benefits Of Breastfeeding For Mother And Baby - News18 - August 5th, 2020
- Stem Cells Cryopreservation Equipments Market to grow significantly in future | Worthington Industries,Cesca Therapeutics,Shengjie Cryogenic Equipment... - August 3rd, 2020
- Stem Cell Therapy Market Latest Trends, Development, Revenue, Demand And Forecast To 2022 - Market Research Correspondent - August 3rd, 2020
- Global trade impact of the Coronavirus Synthetic Stem Cells Market Report 2020-2026 Research Insights 2020 Global Industry Outlook Shared in Detailed... - July 30th, 2020
- World's First Plant and Cell Based Bacon and Pork Belly - One Green Planet - July 30th, 2020
- FDA Approves New CAR-T Therapy for Mantle Cell Lymphoma - Cancer Health Treatment News - July 26th, 2020
- Of mice and SARS-CoV-2 - The Hindu - July 26th, 2020
- Ruxolitinib passes another PhIII test for graft-versus-host disease, a win for Incyte and Novartis - Endpoints News - July 24th, 2020
- Study finds the real reason you get goosebumps - Big Think - July 24th, 2020
- Harvard study finds that stem cell stimulation gives us goosebumps - New Atlas - July 24th, 2020
- Celltex Therapeutics Webinar | Houston, TX Patch - Patch.com - July 24th, 2020
- Bioreactors Market Forecast to 2027 Covid-19 Impact and Global Analysis by Product Class, Material, Cell ; Molecule ; Technology ; End User, and... - July 24th, 2020
- Association of TNF- Gene Expression and Release in Response to | DMSO - Dove Medical Press - July 24th, 2020
- 'Missing link': Bayer, Morningside help catapult a new kind of delivery tech to cell and gene therapy - Endpoints News - July 24th, 2020
- Regulation of advanced therapy medicinal products in the EU - Regulatory Focus - July 18th, 2020
- Coronavirus Drug and Treatment Tracker - The New York Times - July 18th, 2020
- UCSD Researchers Discover and Manipulate Different Aging Processes in Cells - Times of San Diego - July 18th, 2020
- Restorative therapies for erectile dysfunction: Where are we at in 2020? - Urology Times - July 18th, 2020
- Flow Cytometry Market Size Forecast to Reach $6.71 Billion by 2025 - Reported Times - July 18th, 2020
- Cryopreservation Equipments in Stem Cells Market Innovative Technology Growth, Business Strategies and Trend 2027 - Owned - July 16th, 2020
- Advanced Therapy Medicinal Products Market Break Down By Leading Companies, Countries, Applications, Challenges, Opportunities And Forecast 2020-2026... - July 16th, 2020
- Foodtech of the future post-COVID: Robot bartenders, insects and cannabis drinks - EU-Startups - July 14th, 2020
- 7 Benefits of Bee Pollen - What Are the Benefits of Bee Pollen - Prevention.com - July 14th, 2020
- Pancreatic cancer hides from the immune system by destroying the cell's danger signal - Massive Science - July 14th, 2020
- Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market 2020 Size By Product Types, End-Users, Regional Outlook, Growth Potential, Price... - July 10th, 2020
- Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy - StreetInsider.com - July 10th, 2020
- Fasting is not starvation or a fad, it is a discipline: Luke Coutinho - The Indian Express - July 10th, 2020
- FDA Approves Talaris Therapeutics' IND for Its Allogeneic Cell Therapy FCR001 to Be Evaluated in Patients With a Severe Form of Scleroderma -... - July 10th, 2020
- Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration - BioSpace - July 10th, 2020
- Blood factors transfer beneficial effects of exercise on neurogenesis and cognition to the aged brain - Science Magazine - July 10th, 2020
- Ziopharm Oncology Announces Initiation of Phase 1 Trial Evaluating Rapid Personalized Manufacturing CAR-T Technology in Patients with Relapsed CD19+... - July 10th, 2020
- Benefits of Ashwagandha tea and how to make it - TheHealthSite - July 10th, 2020
- Live Cell Imaging Market Poised for Steady Growth in the Future 2020-2024 - Jewish Life News - July 10th, 2020
- Hematopoietic Stem Cells Transplantation Market to Eyewitness Massive Growth by 2028: Leading Key Players Kite Pharma, Thermo Fisher Scientific,... - July 8th, 2020
- One common infection could kill our baby girl but one simple act could change her life forever - The Sun - July 8th, 2020
- Multidrug Combinations and CAR T-Cell Therapies for Heavily Pretreated Multiple Myeloma Shine at ASCO - Targeted Oncology - July 8th, 2020
- Vitamin P: Overview, Benefits, and More - Healthline - July 8th, 2020
- How COVID-19 Pandemic Will Impact Australia & New Zealand Research Antibodies Market Business Opportunity, And Growth 2020-2026 - 3rd Watch News - July 6th, 2020